Microbix Schedules Release of Results for Q3 Fiscal 2024
Microbix Schedules Release of Results for Q3 Fiscal 2024
Results Release and Webinar Discussion on Morning of August 14, 2024
2024 年 8 月 14 日上午的结果发布和网络研讨会讨论
MISSISSAUGA, Ontario, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix), a life sciences innovator, manufacturer, and exporter, announces that it expects to file the financial statements and management disclosure and analysis for its third quarter of fiscal 2024 ended June 30, 2024 ("Q3 2024") prior to the start of trading on August 14, 2024. Furthermore, at 10:00 AM ET on that day, Microbix intends to hold a webinar discussion of Q3 2024 results with its CEO, CFO, and COO.
安大略省密西沙加,2024年8月7日(GLOBE NEWSWIRE)——生命科学创新者、制造商和出口商Microbix Biosystems Inc.(多伦多证券交易所股票代码:MBX,OTCQX:MBXBF,Microbix)宣布,预计将在2024年6月30日之前提交截至2024年6月30日的2024财年第三季度(“2024年第三季度”)的财务报表以及管理层披露和分析交易于 2024 年 8 月 14 日开始。此外,美国东部时间当天上午10点,Microbix打算与其首席执行官、首席财务官和首席运营官举行网络研讨会,讨论2024年第三季度的业绩。
Investor and shareholders can participate in the webinar, hosted by Adelaide Capital, by registering at: .
投资者和股东可以通过以下地址注册参加由阿德莱德资本主办的网络研讨会:。
It will also be live-streamed to YouTube at: .
它还将在YouTube上直播,网址为:.
Telephone participation in the webinar can be arranged by contacting Microbix or Adelaide Capital at the contact numbers provided at the end of this news release.
可以通过拨打本新闻稿末尾提供的联系电话联系Microbix或Adelaide Capital来安排电话参加网络研讨会。
A replay of the webinar will also be made available on Adelaide Capital's YouTube channel.
网络研讨会的重播也将在阿德莱德资本的YouTube频道上播出。
About Microbix Biosystems Inc.
Microbix Biosystems Inc. creates proprietary biological products for human health, with over 100 skilled employees and annualized sales now targeting C$ 2.0 million per month. It makes and exports a wide range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its antigens drive the antibody tests of approximately 100 diagnostics makers, while QAPs are sold to clinical lab accreditation organizations, diagnostics companies, and clinical labs. Microbix QAPs are now available in over 30 countries, supported by a network of international distributors. Microbix is ISO 9001 & 13485 accredited, U.S. FDA registered, Australian TGA registered, Health Canada establishment licensed, and provides CE marked products.
关于 Microbix Biosystems Inc.
Microbix Biosystems Inc. 为人类健康生产专有生物制品,拥有超过100名熟练员工,现在的年化销售额目标是每月200万加元。它为全球诊断行业生产和出口各种关键成分和设备,尤其是用于免疫分析的抗原及其实验室质量评估产品(QAP),这些产品支持临床实验室能力测试、支持检测开发和验证或帮助确保临床诊断工作流程的质量。它的抗原推动了大约100家诊断制造商的抗体测试,而QAP则出售给临床实验室认证机构、诊断公司和临床实验室。在国际分销商网络的支持下,Microbix QAPs现已在30多个国家上市。Microbix 已获得 ISO 9001 和 13485 认证,美国食品药品管理局注册,澳大利亚 TGA 注册,加拿大卫生部机构获得许可,并提供带有 CE 标志的产品。
Microbix also applies its biological expertise and infrastructure to develop other proprietary products and technologies, most notably Kinlytic urokinase, a biologic thrombolytic drug used to treat blood clots, and reagents or media to support molecular diagnostic testing (e.g., its DxTM for patient-sample collection). Microbix is traded on the TSX and OTCQX, and headquartered in Mississauga, Ontario, Canada.
Microbix还运用其生物专业知识和基础设施开发其他专有产品和技术,最著名的是Kinlytic urokinase,一种用于治疗血栓的生物溶栓药物,以及支持分子诊断测试的试剂或介质(例如用于患者样本收集的DxTM)。Microbix在多伦多证券交易所和OTCQX上市,总部位于加拿大安大略省密西沙加。
Forward-Looking Information
This news release includes "forward-looking information," as such term is defined in applicable securities laws. Forward-looking information includes, without limitation, expected timing of release of financial results, intended discussion of financial results or the outlook for the business, risks associated with its financial results and stability, its current or future products, development projects such as those referenced herein, sales to foreign jurisdictions, engineering and construction, production (including control over costs, quality, quantity and timeliness of delivery), foreign currency and exchange rates, maintaining adequate working capital and raising further capital on acceptable terms or at all, and other similar statements concerning anticipated future events, conditions or results that are not historical facts. These statements reflect management's current estimates, beliefs, intentions, and expectations; they are not guarantees of future performance. The Company cautions that all forward looking information is inherently uncertain, and that actual performance may be affected by many material factors, some of which are beyond the Company's control. Accordingly, actual future events, conditions and results may differ materially from the estimates, beliefs, intentions, and expectations expressed or implied in the forward-looking information. All statements are made as of the date of this news release and represent the Company's judgement as of the date of this new release, and the Company is under no obligation to update or alter any forward-looking information.
前瞻性信息
本新闻稿包括 “前瞻性信息”,该术语在适用的证券法中定义。前瞻性信息包括但不限于公布财务业绩的预期时间、对财务业绩或业务前景的预定讨论、与其财务业绩和稳定性相关的风险、其当前或未来产品、开发项目(如本文提及的开发项目)、向外国司法管辖区的销售、工程和施工、生产(包括控制成本、质量、数量和交付及时性)、外币和汇率、维持充足的营运资金和进一步筹集资金以可接受的条件或完全按可接受的条件计算的资本,以及其他与预期的未来事件、条件或结果有关的非历史事实的类似陈述。这些陈述反映了管理层当前的估计、信念、意图和预期;它们不能保证未来的表现。该公司警告说,所有前瞻性信息本质上都是不确定的,实际业绩可能会受到许多重大因素的影响,其中一些因素是公司无法控制的。因此,未来的实际事件、条件和结果可能与前瞻性信息中表达或暗示的估计、信念、意图和预期存在重大差异。所有陈述均自本新闻稿发布之日起作出,代表公司截至本新闻稿发布之日的判断,公司没有义务更新或修改任何前瞻性信息。
Please visit or for recent Microbix news and filings.
请访问或查看最近的 Microbix 新闻和文件。
For further information, please contact Microbix at:
欲了解更多信息,请通过以下方式联系 Microbix:
Cameron Groome, CEO (905) 361-8910 |
Jim Currie, CFO (905) 361-8910 |
Deborah Honig, Investor Relations Adelaide Capital Markets (647) 203-8793 ir@microbix.com |
首席执行官卡梅隆·格鲁姆 (905) 361-8910 |
吉姆·柯里, 首席财务官 (905) 361-8910 |
黛博拉·霍尼格, 投资者关系 阿德莱德资本市场 (647) 203-8793 ir@microbix.com |
Copyright 2024 Microbix Biosystems Inc.
Microbix, DxTM, Kinlytic, & QAPs are trademarks of Microbix Biosystems Inc.
版权所有 2024 Microbix 生物系统公司
Microbix、DxTM、Kinlytic 和 QAP 是 Microbix Biosystems Inc. 的商标。